Optimization of Eudragit RS100 Nanocapsule Formulation for Encapsulating Perillyl Alcohol and Temozolomide Using...

Area of Science:

• Nanotechnology
• Pharmacology
• Oncology

Background:

• Glioblastoma is a challenging intracranial tumor.
• The blood-brain barrier (BBB) limits conventional glioblastoma treatment efficacy.

Purpose of the Study:

• To develop and optimize a nanoencapsulated system for intranasal delivery of temozolomide (TMZ) and perillyl alcohol (POH).
• To circumvent blood-brain barrier limitations for enhanced glioblastoma therapy.

Main Methods:

• Utilized Eudragit RS100 as the encapsulation matrix.
• Employed a factorial design to optimize encapsulation parameters.
• Characterized nanocapsules using dynamic light scattering, zeta potential analysis, SEM, and HPLC.

Main Results:

• Optimized nanocapsules exhibited a mean diameter of 253 ± 52 nm with uniform size distribution (PDI: 0.145 ± 0.037).
• Zeta potential of +20 mV indicated good colloidal stability.
• Achieved encapsulation efficiencies of 3.7% for POH and 28.5% for TMZ.

Conclusions:

• The developed nanoencapsulated system shows promise for intranasal glioblastoma treatment.
• This approach may improve clinical outcomes and reduce treatment toxicity by overcoming BBB challenges.